Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.37 |
| ▸ | VNN1 | O95497 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23680749 | 0.89 | HPGD (0.53) | HPGDMGLL | |
| SCHEMBL23680681 | 0.89 | HPGD (0.64) | HPGDMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL31038242 | 0.87 | HPGD (0.50) | HPGDMGLLSMN1; SMN2PRKAA2VNN1 | |
| SCHEMBL24942616 | 0.87 | HPGD (0.50) | HPGDMGLLSMN1; SMN2PRKAA2VNN1 | |
| SCHEMBL23680569 | 0.87 | HPGD (0.53) | HPGDMGLLL3MBTL3L3MBTL1VNN1 | |
| SCHEMBL29565034 | 0.85 | HPGD (0.62) | HPGDMGLL | |
| SCHEMBL23680738 | 0.85 | HPGD (0.62) | HPGDMGLL | |
| Cyclopropane Carboxylic Acid SCHEMBL28887293 | 0.85 | HPGD (0.44) | HPGDMGLLPRKAA2VNN1HRH3 | |
| SCHEMBL23680692 | 0.84 | HPGD (0.51) | HPGDMGLLL3MBTL3L3MBTL1VNN1 | |
| SCHEMBL31038243 | 0.84 | HPGD (0.49) | HPGDMGLLSMN1; SMN2VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345702-B1 | PGDH inhibitors and methods of making and using | MYOFORTE THERAPEUTICS, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2021151014-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | MYOFORTE THERAPEUTICS, INC. (US) | 2021-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345702-B1 | PGDH inhibitors and methods of making and using | HPGD, HPGDS, PTGS1 | HPGD 1/4885MGLL 494/4885L3MBTL3 4241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.